Bank of Montreal Can acquired a new stake in shares of NICE Ltd. (NASDAQ:NICE – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 8,332 shares of the technology company’s stock, valued at approximately $1,908,000.
A number of other hedge funds have also made changes to their positions in the stock. Benjamin F. Edwards & Company Inc. increased its holdings in shares of NICE by 9.9% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 554 shares of the technology company’s stock valued at $127,000 after acquiring an additional 50 shares during the last quarter. Legal & General Group Plc grew its holdings in NICE by 0.3% in the 2nd quarter. Legal & General Group Plc now owns 14,955 shares of the technology company’s stock valued at $2,878,000 after buying an additional 51 shares during the last quarter. Capital Insight Partners LLC grew its holdings in NICE by 3.4% in the 1st quarter. Capital Insight Partners LLC now owns 1,590 shares of the technology company’s stock valued at $364,000 after buying an additional 52 shares during the last quarter. Moors & Cabot Inc. grew its holdings in NICE by 3.1% in the 1st quarter. Moors & Cabot Inc. now owns 1,784 shares of the technology company’s stock valued at $408,000 after buying an additional 54 shares during the last quarter. Finally, Loomis Sayles & Co. L P grew its holdings in NICE by 25.2% in the 1st quarter. Loomis Sayles & Co. L P now owns 298 shares of the technology company’s stock valued at $65,000 after buying an additional 60 shares during the last quarter. Institutional investors and hedge funds own 63.58% of the company’s stock.
NICE Price Performance
NICE stock opened at $169.75 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.31 and a quick ratio of 2.31. The company has a market capitalization of $10.80 billion, a PE ratio of 36.90, a price-to-earnings-growth ratio of 2.03 and a beta of 0.89. NICE Ltd. has a one year low of $149.54 and a one year high of $231.54. The business has a 50 day simple moving average of $170.15 and a 200 day simple moving average of $192.79.
Analyst Ratings Changes
NICE has been the topic of a number of research analyst reports. Morgan Stanley raised NICE from an “equal weight” rating to an “overweight” rating and lowered their target price for the company from $225.00 to $220.00 in a report on Monday, October 16th. Oppenheimer lowered their target price on NICE from $250.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, October 5th. TheStreet lowered NICE from a “b-” rating to a “c+” rating in a report on Tuesday, September 12th. Royal Bank of Canada reissued an “outperform” rating and set a $238.00 price objective on shares of NICE in a report on Thursday, October 5th. Finally, JMP Securities reissued a “market outperform” rating and set a $343.00 price objective on shares of NICE in a report on Monday, October 9th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $249.00.
Check Out Our Latest Research Report on NICE
NICE Profile
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for CX that discovers automation opportunities for self-service; digital-entry points solutions that enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing.
Read More
- Five stocks we like better than NICE
- What Are the U.K. Market Holidays? How to Invest and Trade
- Investing in large cap stocks: Diving into big caps
- How to Read Stock Charts for Beginners
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- How to Invest in the Entertainment Industry
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for NICE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NICE and related companies with MarketBeat.com's FREE daily email newsletter.